Abstract 13213: Sex-related Differences in Symptom Status Among Patients With Atrial Fibrillation
Background: Many patients with atrial fibrillation (AF) have symptoms related to the arrhythmia, but little is known about sex-specific differences. We therefore prospectively assessed sex-specific differences in health perception, overall symptom status and a comprehensive panel of specific symptoms in a large cohort of AF patients.
Methods: We performed a prospective multicenter observational cohort study of 1550 AF patients, who were enrolled between 2010 and 2014. All patients completed questionnaires about personal characteristics, co-morbidities and symptoms on a yearly basis.
Results: Mean age was 70±11 years among women and 67±12 years among men. Health perception on a visual analogue scale was significantly lower in women than in men (67±20 vs. 72±18 respectively; p< 0.0001). Compared to men, more women had any symptoms (85.0% vs. 68.3%; p< 0.0001), palpitations (65.2% vs. 44.4%; p< 0.0001), dizziness (25.6% vs. 13.5%; p< 0.0001), dyspnea (35.7% vs. 21.8; p< 0.0001) and fatigue (25.3 vs. 19.1; p= 0.006). One year after baseline, symptoms decreased in both sexes, but remained more frequent in women (49% vs. 33%, p< 0.0001). These findings persisted after two years (48% vs. 32%, p< 0.0001) and after three years (41% vs. 31%, p= 0.02). After multivariable adjustment, female sex remained an independent predictor for a lower health perception (ß = -5.4 [95% confidence (CI) -7.4; -3.3] p< 0.0001), any symptoms (odds ratio (OR) 3.0 [95%CI 2.2; 4.1] p< 0.0001), palpitations (OR 2.8 [95%Cl 2.2; 3.7] p< 0.0001), dizziness (OR 2.3 [95%Cl 1.7; 3.1] p< 0.0001), dyspnea (OR 2.0 [95%Cl 1.5; 2.6] p< 0.0001) and fatigue (OR 1.7 [95%Cl 1.3; 2.3] p< 0.0001). Similar results were obtained one year after baseline (follow-up) as presented in the Table.
Conclusions: Women with AF had a substantially higher symptom burden and a lower health perception than men. These relationships persisted after comprehensive multivariable adjustment and during prospective follow-up.
Author Disclosures: S. Blum: None. C. Muff: None. P. Ammann: None. P. Erne: None. G. Moschovitis: None. M. Di Valentino: None. D. Shah: Honoraria; Modest; Bristol-Myers-Squibb, Pfizer, Daiichi-Sankyo. J. Schläpfer: Consultant/Advisory Board; Modest; Daiichi-Sankyo, Bayer, Boehringer-Ingelheim. A. Fischer: None. T. Merkel: None. M. Kühne: Research Grant; Modest; Unrestricted grants from: Sanofi Aventis, Bayer and Boehringer Ingelheim. Speakers Bureau; Modest; Boston Scientific, St. Jude Medical and Biotronik. Consultant/Advisory Board; Modest; Sorin, Boehringer Ingelheim, Bayer, Sanofi Aventis, Novartis and MSD. Other; Modest; Proctor for Medtronic (Cryoballoon). C. Sticherling: None. S. Osswald: None. D. Conen: Research Grant; Significant; Swiss National Science Foundation (PP00P3_133681 and PP00P3_159322). Other Research Support; Modest; Bayer, Bristol-Myers-Squibb, Pfizer and Daiichi-Sankyo. Honoraria; Modest; Bayer, Bristol-Myers-Squibb, Pfizer, Boehringer Ingelheim and Daiichi-Sankyo.
- © 2016 by American Heart Association, Inc.